- Price Band of ₹91/– ₹96/- per Equity Share bearing face value of ₹10/- each (“Equity Shares”)
- Bid/Offer Opening Date – Wednesday, June 18, 2025 and Bid/Offer Closing Date – Friday, June 20, 2025.
- Minimum Bid Lot is 1200 Equity Shares and in multiples of 1200 Equity Shares thereafter.
Mumbai, June 16, 2025: Influx Healthtech Limited has fixed the price band of ₹91/- to ₹96/- per Equity Share of face value ₹10/- each for its maiden initial public offer.
The Initial Public Offering (“IPO” or “Offer”) of the Company will open on Wednesday, June 18, 2025, for subscription and close on Friday, June 20, 2025. Investors can bid for a minimum of 1200Equity Shares and in multiples of 1200Equity Shares thereafter.
The IPO is a mix of fresh issue of up to 50,00,400 equity shares and an offer for sale up to 11,00,400 equity shares by Munir Abdul Ganee Chandniwala.
The proceeds from its fresh issuance will be utilized to the extent of Rs 22.49 crore for funding capital expenditure requirements for setting up of manufacturing facility for Nutraceutical Division; Rs 11.48 Crore for setting up of manufacturing facility for Veterinary Food Division; Rs 2.75 crore for Purchase of Machineries for Homecare and Cosmetic Division.
Mumbai-based Influx Healthtech Limited was established in 2020 by Mr. Munir Abdul Ganee Chandniwala, healthcare focused company specialising in contract manufacturing. Since its inception, the company has established itself as a reliable Contract Development and Manufacturing Organization (CDMO), offering specialized services to a wide range of clients across various industries.
The company operates 4 manufacturing facilities located in Thane, Maharashtra, covering a total area of approximately 9,676 square feet, 13,000 square feet, 14,000 square feet and 14,000 square feet, respectively. The Company has an expertise that spans the production of Dietary and Nutritional Supplements, Cosmetics, Ayurvedic/Herbal Products, Veterinary Feed Supplements, Homecare Products, Active Pharmaceutical Ingredients (APIs), and finished dosage forms, including tablets, capsules, and injectables.
The company’s manufacturing division offers Dietary/Nutritional Supplement, Cosmetics, and Ayurvedic / Herbal products Veterinary Feed Supplements, Homecare Products, Active Pharmaceutical Ingredients (APIs), and finished dosage forms, including tablets, capsules, and injectables.
It has a long-standing relationship with clients which includes Bling Brands Private Limited, Evoq Business Ventures LLP, HSHS Nutraceuticals Limited, Bruder Life Science, and Bigflex Lifescience Private Limited.
Rarever Financial Advisors Private Limited is the sole book-running lead manager, and Maashitla Securities Private Limited is the registrar of the issue.
The Offer is being made through the book-building process, wherein not more than 50% of the net offer shall be available for allocation on a proportionate basis to qualified institutional buyers, not less than 15% of the offer shall be available for allocation to non-institutional bidders, and not less than 35% of the offer shall be available for allocation to retail individual bidders.
Leave a Reply